The NICE Guideline (NG23) 2015 Menopause: Diagnosis and Management states that ‘women who are likely to go through the menopause as a result of medical or surgical treatment should be offered support and information about the menopause and fertility before they have their treatment, and a referral to a Health Care Professional with expertise in the menopause’. To investigate whether discussion about the surgery causing the menopause, and advice on possible treatments had been documented, I conducted a retrospective study of women undergoing bilateral oophorectomy at a central London teaching hospital from 1st April 2018 to 30th September 2018. Only 30% of women (8 out of 27) in this study had documentary evidence of having received menopause advice around the time of bilateral oophorectomy.
National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline [NG23]. https://www.nice.org.uk/guidance/ng23 (2015, accessed 2 May 2019).
2.
DratvaJGómez RealFSchindlerC, et al.Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause2009; 16(2): 385–394.
BaskindELovellR. Preoperative counselling prior to procedures resulting in an iatrogenic menopause. BJOG: An Int J Obstet Gynaecol2016; 123(4): 21.
5.
RichardsonAWestECustM. Hormone replacement therapy in pre-menopausal women undergoing bilateral salpingo-oophorectomy for benign disease: a review of practice. Post Reprod Health2017; 23(2): 63–70.
6.
JohansenNLiavaagAHTanboTG, et al.Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol2016; 140(1): 101–106.
7.
TuckerPEBulsaraMKSalfingerSG, et al.The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy. Maturitas2016; 85: 42–48.
8.
OzdemirSCelikCGörkemliH, et al.Compared effects of surgical and natural menopause on climacteric symptoms, osteoporosis, and metabolic syndrome. Int J Gynaecol Obstet2009; 106(1): 57–61.
9.
European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POIWebberLDaviesM, et al.ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod2016; 31(5): 926–937.
10.
ParkerWHBroderMSChangE, et al.Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol2009; 113(5): 1027–1037.
11.
RoccaWAGazzuola RoccaLSmithCY, et al.Bilateral oophorectomy and accelerated aging: cause or effect?J Gerontol A Biol Sci Med Sci2017; 72(9): 1213–1217.
12.
IslamRCartwrightRZhenX, et al. Selected oral communication session, session 69: endocrinology and pof Wednesday 6 July 2011 14:00–15:45. The impact of premature ovarian failure on quality of life: results from the UK 1958 birth cohort. Hum Reprod. 2011; 26(1): i108–i110.
13.
BhatnagarPWickramasingheKWilliamsJ, et al.The epidemiology of cardiovascular disease in the UK 2014. Heart2015; 101(15): 1182–1189.
14.
AtsmaFBartelinkM-LELGrobbeeDE, et al.Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause2006; 13(2): 265–279.
15.
Roeters van LennepJEHeidaKYBotsML, et al.Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol2016; 23(2): 178–186.
16.
RiveraCMGrossardtBRRhodesDJ, et al.Increased cardiovascular mortality after early bilateral oophorectomy. Menopause2009; 16(1): 15–23.
17.
GallagherJCLevineJP. Preventing osteoporosis in symptomatic postmenopausal women. Menopause2011; 18(1): 109–118.
18.
CompstonJCooperACooperC, et al.Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas2009; 62(2): 105–108.
19.
PopatVBCalisKAVanderhoofVH, et al.Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab2009; 94(7): 2277–2283.
20.
GeorgakisMKBeskou-KontouTTheodoridisI, et al.Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology2019; 106: 9–19.
21.
PhungTKTWaltoftBLLaursenTM, et al.Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord2010; 30(1): 43–50.
22.
RoccaWAGrossardtBRShusterLT, et al.Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener Dis2012; 10(1–4): 175–178.
23.
WoykaJ. Consensus statement for non-hormonal-based treatments for menopausal symptoms. Post Reprod Health2017; 23(2): 71–75.
24.
RossouwJEMansonJEKaunitzAM, et al.Lessons learned from the women’s health initiative trials of menopausal hormone therapy. Obstet Gynecol2013; 121(1): 172–176.
25.
BeralVMillion Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million women study. Lancet2003; 362(9382): 419–427.
26.
ClarksonTBMeléndezGCApptSE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause2013; 20(3): 342–353.
27.
SchierbeckLLRejnmarkLToftengCL, et al.Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012; 345: e6409.
28.
HodisHNMackWJHendersonVW, et al.Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med2016; 374(13): 1221–1231.
29.
BoardmanHMPHartleyLEisingaA, et al.Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev2015; (3):CD002229.
30.
CanonicoMCarcaillonLPlu-BureauG, et al.Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke2016; 47(7): 1734–1741.
31.
HillardTAbernethyKHamodaH, et al.Management of the Menopause. 6th ed.London: British Menopause Society; 2017.
32.
CanonicoMOgerEPlu-BureauG, et al.Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation2007; 115(7): 840–845.
33.
CushmanMKullerLHPrenticeR, et al.Estrogen plus progestin and risk of venous thrombosis. JAMA2004; 292(13): 1573–1580.
34.
VinogradovaYCouplandCHippisley-CoxJ. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ2019; 364: k4810.
35.
ShiL-FWuYLiC-Y. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause2016; 23(4): 417–424.
36.
SturdeeDW. Endometrial cancer and HRT. Rev Gynaecol Pr2005; 5(1): 51–56.
Faculty of Sexual and Reproductive Healthcare. UK medical eligibility for contraceptive use (UKMEC). https://www.fsrh.org/ukmec/ (2016, accessed 2 May 2019).
39.
CartwrightBRobinsonJSeedPT, et al.Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab2016; 101(9): 3497–3505.
40.
PanayN. British menopause society tools for clinicians: testosterone replacement in menopause. Post Reprod Health2019; 25(1): 40–42.
41.
SarrelPMSullivanSDNelsonLM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril2016; 106(7): 1580–1587.
42.
MørchLSLøkkegaardEAndreasenAH, et al.Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol2012; 175(12): 1234–1242.
43.
Committee on Gynecologic Practice. ACOG committee opinion-hormone replacement therapy in women treated for endometrial cancer. Int J Gynaecol Obstet2001; 73(3): 283–284.
44.
SiyamTCarbonJRossS, et al.Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): a narrative review. Maturitas2019; 120: 68–76.
45.
Lindh-ÅstrandLHoffmannMJärvstråtL, et al.Hormone therapy might be underutilized in women with early menopause. Hum Reprod2015; 30(4): 848–852.
46.
BachelotANicolasCGricourtS, et al.Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One2016; 11(12): e0164638.
